PharmAccess African Studies to Evaluate Resistance - Monitoring Study (PASER-M)
PASER-M assesses the prevalence and incidence of HIV drug resistance, mutational patterns, and factors in persons initiating anti-retroviral therapy (ART) in Kenya, Nigeria, South Africa, Uganda, Zambia, and Zimbabwe. Recruited participants were at least 18 years old and eligible for first-line ART. At baseline, over 2,800 participants were included in the study. Participants were followed up every 3 months.
Study design
Cohort - clinical
Number of participants at first data collection
2,895 (participants)
Age at first data collection
≥ 18 years (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
2007
Primary Institutions
Amsterdam Institute for Global Health and Development (AIGHD)
Coptic Hope Center
Institute of Human Virology Nigeria (IHVN)
Lagos University Teaching Hospital (LUTH)
Lusaka Trust Hospital
Links
Profile paper DOI
Funders
African partnership for capacity development and clinical interventions against poverty-related diseases (NACCAPII): ART-A phase I, ART-A phase II
Embassy of the Kingdom of the Netherlands in Pretoria Regional HIV/AIDS Program
Heineken Africa Foundation
Jura Foundation
Ministry of Foreign Affairs
Ongoing?
No
Data types collected
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- Secondary data
- None
- None
- Healthcare data
Engagement
Keywords
